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ISSUES IN MEDICINE South African administrative laws and thus the operations of
the Council.
THE MEDICINES REGULATORY
SYSTEM IN SOUTH AFRICA -
REVIEW AND PROPOSALS FOR
REFORM
Review and reform of the South African national drug
regulatory authority, the Medicines Control Council, is long
overdue. Other countries have benefited in recent years from
independent examination of their systems of medicines control,
and it was hoped that the same might be achieved for South
Africa. There were fundamental issues to be addressed,
including the need to decide how to place a regulatory
framework for control of complementary medicines, and
personnel change in a number of the expe~t committees of the
Council and the secretariat to meet the needs of transformation.
(The Council itself did not have that problem, having been
appointed by the Minister of Health in 1996.)
WEAK ESSES OF THE MCC
It is inevitable in the adversarial climate of drug regulation that
there will be criticism of the national authority. Some of this is
justified. For example: .
1. Leadership is vested in too few people, given that all the
members of the Council have demanding full-time positions in
their own institutions. There have been chronic difficulties in
recruiting and keeping competent full-time scientists and
medically qualified personnel in the secretariat.
2. A formula for successfully communicating results,
decisions and explanations for Council policy to the public has
not been adequately achieved. It becomes particularly obvious
when intensity of public and media interest is high. This is
further complicated by the legislative requirements that
prevent the Council from divulging details that might
compromise intellectual property of the applicants.
3. Perhaps more than anything else, the deficiencies of the
Council are reflected in its inilbility to translate deci ion-taking
into a supportive programme of drug information provision,
reactive as well as proactive, for the health professions and the
public. Clinics and other primary health care facilities, whose
need is greatest, particularly require drug information and
advice on rational drug use. This deficiency has been one of
resources and inability of the Council to persuade the
authorities of the importance of drug information.
What has never been suggested in criticism of the MCC are
impropriety, dishonesty, graft, irregularities, lack of fairness, or
departure from the principles of natural justice which govern
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THE PROPOSED SOLUTIO
Over January - March 1998 a review team, appointed by the
Minister of Health, considered the difficulties and criticisms
under which the MCC currently labours. The review team has
proposed as its solution, in place of the MCc, a central
management team, linked directly to the Minister of Health
and advised by two technical committees dealing with
conventional and complementary (traditional) medicines,
respectively. The overarching authority will be stronger in
management than in science and clinical practice. Review of
complementary medicines will fall within the same authority,
which has been the preferred approach of the present Council.
New senior management and director positions will be created.
Training programmes for staff will be strengthened and further
developed.
Any proposal for a new drug regulatory authority needs to
rest on foundations which have proved in the experience of the
Council to be firm.
SPECIAL FEATURES OF THE MCC
Certain features of the CC have proved to be special to the
country, and they have served the nation well. They have been
underpinned by a number of foundation principles. These
principles include:
1. Emphasis on scientific and clinical principles at every level
of decision taking.
2. Inclusion of a broad spectrum of university and clinical
personnel, and delegation of the decision-making process to
the lowest responsible committee level possible, while allowing
adequate opportunity for peer review before final decisions are
taken. (Countryvvide, more than 120 consultants in pharmacy
and medicine serve on expert committees of the Council,
representing 11 of the country's universities.)
3. Application of t.he highest ethical and professional
standards at every level of operation of the Council and its
secretariat.
4. Flexible central administrative procedures linked to
systematic staff training programmes within the secretariat.
When regulatory decisions have already been taken elsewhere,
an accelerated review system is implemented that enables
rapid review, within a short time (weeks to several months), for
important new developments. The anti-AIDS drug zidovudine,
for example, was approved for use in South Africa within 17
days of its having been filed for registration.
5. Insistence on decision making of the Council at every level
being vested in the hands of individuals who themselves are
actively involved in the care of patients, teaching and research.
The highest standards have been set for the conduct of
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clinical trials. This applies to the requirements for safety,
toxicology, quality, scientific integrity and clinical relevance of
new chemical entities before they are given to humans for
experimental purposes. The MCC also requires independent
approval by institutional ethics committees of all clinical trials.
It is vital for a developing country that there should be no
compromise in the standards of human experimentation, in
order to prevent exploitation.
Whenever decisions of the MCC are challenged, this is dealt
with by the Council flexibly, rapidly (within 30 days) and
without cost to the applicants.
MARKERS OF PERFORMANCE
There are several independent markers of performance of the
MCC which the new authority should aim to strengthen in a
manner that remains efficient and economical. These include:
1. An overall review time for approval of new medicines
(brand products and generic medicines) that has been
independently rated as being one of the five shortest in the
world.
2. The MCC has served for a number of years as a training
centre for drug regulators from developing countries
elsewhere, and it is officially designated as such by the World
Health Organisation. Many colleagues from throughout the
world have received training in drug regulation at the MCC.
3. The MCC has taken a leading role in bringing about a
regional plan in southern and East Africa for collaboration in
sharing of drug regulatory decisions and policy.
4. The average turnover time for evaluation of clinical trials
is 6 weeks, and this has been so for many years despite the
ever-increasing number of applications.
5. The system of adverse drug event reporting and safety
monitoring of medicines in South Africa has attracted
international attention because of its efficiency and its strong
emphasis on an academic and clinical approach.
The secretariat of the MCC has established an exceptional
system of inspection and quality assurance of manufacturers. It
has set the infrastructure for the development of a robust and
flourishing local generic industry that provides the main
proportion of the country's medicines in the public sector, thus
benefiting in particular the poor.
SUMMARY AND CONCLUSION
In planning the future national drug regulatory authority in
South Africa, it is to be hoped that the pillars of scientific and
clinical integrity that have supported the MCC in the past will
be preserved.
It is disturbing that the review committee largely ignored the
modus operandi and the successes of the MCC, so that the
evidence in their report is weak and their recommendations
unsuitable to a modem African country. A drugs review body
must work in such a way that it makes the best use of the
limited manpower and resources available. This will not be
achieved by taking on more bureaucrats.
Peter I Folb
Director, World Health Organisation Collaborating Centre for Drug Policy




ABOUT SAFETY AND EFFICACY
Quinine is extensively used as a contraceptive and sometimes
as an abortifacient. In South Africa quinine sulphate (300 mg
tablets) is available for unrestricted over-the-counter (OTC) sale
in pharmacies. Current recognised uses for quinine are in the
treatment of malaria (particularly chloroquine-resistant
falciparum malaria), for prophylaxis and management of
nocturnal leg cramps, and as a muscle relaxant in myotonia
congenita.' Quinine is also reported to have been used in the
past as an oxytocic to induce and facilitate labour in late
pregnancy,''> and in contraceptive pessaries, although its
spermicidal action is described as weak.''>
Since the source of oral quinine is from private pharmacies,
two surveys (H Govender et al. and E A Amra et al. -
unpublished research projects, University of Durban-Westville,
1993 and 1995) were conducted among 61 pharmacists and
their 76 quinine-purchasing clients in KwaZulu-Natal. It was
found that approximately 50% of the pharmacists sold quinine
to an average of 2 - 6 clients per day. Quinine purchasers were
almost exclusively black women, most between 20 and 29 years
old. Reasons given for the purchase of quinine were mainly
related to 'birth prevention'. Most women took 1 to 2 quinine
tablets orally around the time of sexual intercourse, usually
postcoitally. These doses are too low to be abortifacient. Few
women were concurrently using a conventional contraceptive
method. Some women reported side-effects of skin rash,
tinnitus, blurred vision, nausea and vomiting.
Focus group discussions were also conducted among women
in Cato Crest, an informal settlement in Durban (C Ramoorthy
et al. - unpublished research project, University of Durban- mm
Westville, 1996). All the women interviewed had knowledge of
quinine use in pregnancy prevention, the majority knew of
people who were currently taking quinine, and 23% had used
quinine themselves. Women generally reported taking a single
tablet orally after intercourse. Most regarded quinine as a
popular choice of contraceptive and many believed that it was
